Large-scale testing (Phase 3)Ended earlyNCT04607668
What this trial is testing
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
Who this might be right for
Colorectal Cancer MetastaticMyelosuppression-AdultChemotherapeutic Toxicity
G1 Therapeutics, Inc. 326